159992 创新药
已收盘 10-18 15:00:00
资讯
新帖
简况
10月18日常山药业涨停分析：肝素，减肥药，创新药概念热股
证券之星 · 10-18 15:36
10月18日常山药业涨停分析：肝素，减肥药，创新药概念热股
浙江医药大幅上涨 创新药政策利好
智选洞察 · 10-18 14:34
浙江医药大幅上涨 创新药政策利好
昭衍新药大幅上涨 创新药政策利好
智选洞察 · 10-18 14:18
昭衍新药大幅上涨 创新药政策利好
药明康德大幅上涨 创新药政策利好
智选洞察 · 10-18 14:01
药明康德大幅上涨 创新药政策利好
国投证券：国谈进入常态化阶段 创新药长期放量可期
智通财经 · 10-18 13:37
国投证券：国谈进入常态化阶段 创新药长期放量可期
港股异动 | 医药股多数走强 年内多项利好政策陆续出台 国谈有望促进创新药长期放量
智通财经 · 10-18 10:57
港股异动 | 医药股多数走强 年内多项利好政策陆续出台 国谈有望促进创新药长期放量
医药生物股延续上行趋势 来凯医药(2105)涨超13% 医保谈判望促新一轮创新药放量
金吾财讯 · 10-18 10:27
医药生物股延续上行趋势 来凯医药(2105)涨超13% 医保谈判望促新一轮创新药放量
以岭药业(002603.SZ)化药创新药“G201-Na胶囊”药物临床试验申请获得受理
智通财经 · 10-17 19:44
以岭药业(002603.SZ)化药创新药“G201-Na胶囊”药物临床试验申请获得受理
恒瑞医药“双艾”疗法再闯关FDA，行业新模式下创新药“出海”更汹涌
红星新闻 · 10-17 19:27
恒瑞医药“双艾”疗法再闯关FDA，行业新模式下创新药“出海”更汹涌
关于同意广发证券股份有限公司为万家中证港股通创新药交易型开放式指数证券投资基金提供一般做市服务的公告
上交所 · 10-17
关于同意广发证券股份有限公司为万家中证港股通创新药交易型开放式指数证券投资基金提供一般做市服务的公告
《成都市促进生物医药产业高质量发展的若干政策措施》公开征求意见
美港电讯 · 10-16
《成都市促进生物医药产业高质量发展的若干政策措施》公开征求意见
国泰君安：创新药政策利好有望持续推进 中成药集采或迎加速扩面
智通财经网 · 10-15
国泰君安：创新药政策利好有望持续推进 中成药集采或迎加速扩面
近400只医药股收涨！创新药、中药、连锁药店等板块被券商看好
大河财立方 · 10-14
近400只医药股收涨！创新药、中药、连锁药店等板块被券商看好
关于同意中信证券股份有限公司为万家中证港股通创新药交易型开放式指数证券投资基金提供主做市服务的公告
上交所 · 10-14
关于同意中信证券股份有限公司为万家中证港股通创新药交易型开放式指数证券投资基金提供主做市服务的公告
上海今年第五款国产1类创新药获批上市，获批创新药已超去年
美港电讯 · 10-11
上海今年第五款国产1类创新药获批上市，获批创新药已超去年
礼来制药：将投资15亿元用于苏州工厂产能升级，扩大2型糖尿病和肥胖创新药物的生产规模
财经网 · 10-11
礼来制药：将投资15亿元用于苏州工厂产能升级，扩大2型糖尿病和肥胖创新药物的生产规模
康方生物自主研发创新药获批新适应症
经济参考网 · 10-10
康方生物自主研发创新药获批新适应症
康方生物胃癌适应症创新药获批上市 公司回应：将积极筹备医保谈判
证券日报网 · 10-10
康方生物胃癌适应症创新药获批上市 公司回应：将积极筹备医保谈判
海欣股份： 创新药研发主要包括新药发现、临床研究、药品上市等环节
证券之星 · 10-10
海欣股份： 创新药研发主要包括新药发现、临床研究、药品上市等环节
金十数据整理：每日港股市场要闻速递（10月10日 周四）
美港电讯 · 10-10
金十数据整理：每日港股市场要闻速递（10月10日 周四）
暂无数据
公司概况
公司名称：
--
所属市场：
上市日期：
--
主营业务：
发行价格：
--
{"stockData":{"symbol":"159992","market":"SZ","secType":"STK","nameCN":"创新药","latestPrice":0.728,"timestamp":1729235004000,"preClose":0.699,"halted":0,"volume":799740579,"delay":0,"floatShares":0,"shares":0,"eps":0,"marketStatus":"已收盘","marketStatusCode":5,"change":0.029,"latestTime":"10-18 15:00:00","open":0.695,"high":0.746,"low":0.694,"amount":574000000,"amplitude":0.0744,"askPrice":0.729,"askSize":22292,"bidPrice":0.728,"bidSize":10547,"shortable":0,"etf":1,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1729474200000},"adr":0,"adjPreClose":0.699,"symbolType":"fund","openAndCloseTimeList":[[1729215000000,1729222200000],[1729227600000,1729234800000]],"highLimit":0.769,"lowLimit":0.629,"ibTradeSell":false,"ibTradeBuySell":true,"pbRate":0,"committee":0.423053,"marketValue":0,"floatMarketCap":0,"changeRate":0.0415,"turnoverRate":0,"status":0,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2024-10-21。","discountRate":"0.00%","netWorth":"0.000"},"requestUrl":"/m/hq/s/159992/tweets","defaultTab":"tweets","newsList":[{"id":"2476476972","title":"10月18日常山药业涨停分析：肝素，减肥药，创新药概念热股","url":"https://stock-news.laohu8.com/highlight/detail?id=2476476972","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2476476972?lang=zh_cn&edition=full","pubTime":"2024-10-18 15:36","pubTimestamp":1729236990,"startTime":"0","endTime":"0","summary":"证券之星消息，常山药业10月18日涨停收盘，收盘价18.24元。该股于10点14分涨停，5次打开涨停，截止收盘封单资金为1598.79万元，占其流通市值0.1%。10月18日的资金流向数据方面，主力资金净流入1.9亿元，占总成交额10.09%，游资资金净流出1.27亿元，占总成交额6.77%，散户资金净流出6239.19万元，占总成交额3.32%。近5日资金流向一览见下表：该股为肝素，减肥药，创新药概念热股，当日肝素概念上涨4.03%，减肥药概念上涨3.99%，创新药概念上涨3.37%。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024101800020799.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159992","BK0172","BK0239","BK1161","300255","06978","BK0070","BK1574"],"gpt_icon":0},{"id":"2476947641","title":"浙江医药大幅上涨 创新药政策利好","url":"https://stock-news.laohu8.com/highlight/detail?id=2476947641","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2476947641?lang=zh_cn&edition=full","pubTime":"2024-10-18 14:34","pubTimestamp":1729233286,"startTime":"0","endTime":"0","summary":"10月18日，浙江医药股价大幅上涨，截至14点34分，浙江医药上涨5.25%，报17.25元/股，成交10.57亿元，换手率6.52%。光大证券认为，今年以来，针对创新药领域，多项利好政策陆续出台。诺华将获得该款小分子创新药的全球独家开发及商业化权利。资金动向截止发稿，浙江医药获得主力净流入7455万元，其中超大单流入6850万元，大单流入604万元。主营业务及业绩浙江医药公司主营业务为生命营养品、医药制造类产品及医药商业。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241018154519ab6b1689&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241018154519ab6b1689&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0188","BK0028","159992","BK0239","BK0191","600216"],"gpt_icon":0},{"id":"2476429471","title":"昭衍新药大幅上涨 创新药政策利好","url":"https://stock-news.laohu8.com/highlight/detail?id=2476429471","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2476429471?lang=zh_cn&edition=full","pubTime":"2024-10-18 14:18","pubTimestamp":1729232314,"startTime":"0","endTime":"0","summary":"10月18日，昭衍新药股价大幅上涨，截至14点18分，昭衍新药上涨5.03%，报16.90元/股，成交2.82亿元，换手率2.72%，振幅6.09%。光大证券认为，今年以来，针对创新药领域，多项利好政策陆续出台。诺华将获得该款小分子创新药的全球独家开发及商业化权利。主营业务及业绩昭衍新药公司主营业务为以药物非临床安全性评价服务为主的药物临床前研究服务和实验动物及附属产品的销售业务。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241018142304ab6b0ddf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241018142304ab6b0ddf&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["603127","BK0216","159992"],"gpt_icon":0},{"id":"2476292504","title":"药明康德大幅上涨 创新药政策利好","url":"https://stock-news.laohu8.com/highlight/detail?id=2476292504","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2476292504?lang=zh_cn&edition=full","pubTime":"2024-10-18 14:01","pubTimestamp":1729231260,"startTime":"0","endTime":"0","summary":"10月18日，药明康德股价大幅上涨，截至14点01分，药明康德上涨5.17%，报50.67元/股，突破50元整数关口，成交32.59亿元，换手率2.63%，振幅6.02%。光大证券认为，今年以来，针对创新药领域，多项利好政策陆续出台。诺华将获得该款小分子创新药的全球独家开发及商业化权利。资金动向截止发稿，药明康德获得主力净流入1.57亿元，其中超大单流入1.45亿元，大单流入1188万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241018141337a1e19d57&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241018141337a1e19d57&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1997245094.SGD","603259","159992","LU0456842615.SGD","BK0216","LU1997245177.USD","LU2488822045.USD"],"gpt_icon":0},{"id":"2476425347","title":"国投证券：国谈进入常态化阶段 创新药长期放量可期","url":"https://stock-news.laohu8.com/highlight/detail?id=2476425347","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2476425347?lang=zh_cn&edition=full","pubTime":"2024-10-18 13:37","pubTimestamp":1729229834,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，国投证券发布研报称，2024年医保谈判预计将于近期开启，多个国产创新药将参加本年度医保谈判。本次医保谈判中共有约41个国产创新药进行新增药品谈判。根据国投证券梳理，本次医保谈判中共有约41个国产独家创新药(含引进)通过形式审查：包括2023年7月1日至2024年6月30日之间新获批上市的28个创新药，以及2023年7月1日以前获批上市的13个创新药。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1195788.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1521","BK1515","159992","09926","LU0348783233.USD","LU1720050803.USD","BK1588","LU0417516571.SGD","02096","BK1191","01801","LU2488822045.USD","BK1161","LU0348784397.USD","LU2328871848.SGD","LU1794554557.SGD","LU1969619763.USD","06978","161027","01952","IE00B5MMRT66.SGD","IE00B543WZ88.USD","01177","BK1583","09688","IE00BPRC5H50.USD","BK1589","BK1574"],"gpt_icon":0},{"id":"2476411142","title":"港股异动 | 医药股多数走强 年内多项利好政策陆续出台 国谈有望促进创新药长期放量","url":"https://stock-news.laohu8.com/highlight/detail?id=2476411142","media":"智通财经","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2476411142?lang=zh_cn&edition=full","pubTime":"2024-10-18 10:57","pubTimestamp":1729220234,"startTime":"0","endTime":"0","summary":"光大证券认为，今年以来，针对创新药领域，多项利好政策陆续出台。随着政策落地，创新药发展有望迈入快车道。国投证券指出，国谈进入常态化阶段，创新药长期放量可期。2024年医保谈判预计将于近期开启，多个国产创新药将参加本年度医保谈判。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1195742.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159992","09688","09939","BK1161","06978","BK1574","BK1515","02256","09969","02268","SG9999014674.SGD","02105","LU2488822045.USD","159938","BK1141","BK1588"],"gpt_icon":0},{"id":"2476158024","title":"医药生物股延续上行趋势 来凯医药(2105)涨超13% 医保谈判望促新一轮创新药放量","url":"https://stock-news.laohu8.com/highlight/detail?id=2476158024","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2476158024?lang=zh_cn&edition=full","pubTime":"2024-10-18 10:27","pubTimestamp":1729218425,"startTime":"0","endTime":"0","summary":"金吾财讯| 早盘医药生物板块延续昨日上行趋势集体走高，截至发稿，来凯医药(02105)涨13.39%，再鼎医药(09688)涨7.73%，云顶新耀(01952)涨6.12%。国泰君安研报指出，本轮国家医保谈判结果预计将于四季度出炉。预计于11月份完成谈判并公布结果，预计临床证据充分，患者获益明确的本土创新药有望获益。创新药纳入医保目录后有望迎来准入加速，实现以价换量。该行认为，创新药纳入医保后，有望通过准入覆盖的快速扩大，迎来快速放量。近年来医保谈判环境趋于温和，创新药有望持续获得政策倾斜。2024年的国谈有望延续这一趋势，使得更多创新药品受益。","market":"us","thumbnail":"https://static.szfiu.com/news/20210810/ODRjOWYyNzBiOTE1YTU3YzZjZTEwMTc4Njg3NTQyNA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/ODRjOWYyNzBiOTE1YTU3YzZjZTEwMTc4Njg3NTQyNA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1946087","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1161","BK1588","09688","01952","000808.SH","159992","163118","02105","BK1583","06978"],"gpt_icon":0},{"id":"2476314238","title":"以岭药业(002603.SZ)化药创新药“G201-Na胶囊”药物临床试验申请获得受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2476314238","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2476314238?lang=zh_cn&edition=full","pubTime":"2024-10-17 19:44","pubTimestamp":1729165472,"startTime":"0","endTime":"0","summary":"智通财经APP讯，以岭药业(002603.SZ)发布公告，公司于2024年10月17日收到国家药品监督管理局核准签发的化药创新药“G201-Na胶囊”药物临床试验申请《受理通知书》。G201-Na胶囊项目是公司自主研发、具有独立知识产权的1类化学新药。本品为小分子促性腺激素释放激素(GnRH)受体拮抗剂。可以阻断内源性GnRH与GnRH受体的结合，抑制促黄体生成素和卵泡刺激素等促性腺激素的合成和释放，降低睾酮和雌二醇等性激素水平，维持正常的生殖系统功能。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1195552.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1141","BK1583","BK1574","BK0188","002603","159992","03347","BK0046","BK1576","BK1161","BK0097","BK0239","BK0042","06978"],"gpt_icon":0},{"id":"2476014484","title":"恒瑞医药“双艾”疗法再闯关FDA，行业新模式下创新药“出海”更汹涌","url":"https://stock-news.laohu8.com/highlight/detail?id=2476014484","media":"红星新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2476014484?lang=zh_cn&edition=full","pubTime":"2024-10-17 19:27","pubTimestamp":1729164420,"startTime":"0","endTime":"0","summary":"红星资本局注意到，今年以来，海外授权交易已成医药行业的高频词，尤其是“NewCo模式”。恒瑞医药“双艾疗法”再闯FDA10月15日，恒瑞医药公告，公司重新向FDA提交的“双艾”组合的生物制品许可申请获正式受理。截至目前，注射用卡瑞利珠单抗已在国内获批9个适应症，包括肺癌、肝癌、食管癌、鼻咽癌以及淋巴瘤五大瘤种。据红星资本局不完全统计，截至目前，恒瑞医药、康诺亚、嘉和生物和岸迈生物成功利用“NewCo”模式实现产品“出海”。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202410171927179f4a5401&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202410171927179f4a5401&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0012","BK0028","159992","BK0183","LU0405327148.USD","LU1064131003.USD","600276","BK0060","LU0405327494.USD","LU1328615791.USD","BK0188","LU1064130708.USD","BK0196","BK0239","LU2148510915.USD","LU2488822045.USD"],"gpt_icon":0},{"id":"2476184870","title":"关于同意广发证券股份有限公司为万家中证港股通创新药交易型开放式指数证券投资基金提供一般做市服务的公告","url":"https://stock-news.laohu8.com/highlight/detail?id=2476184870","media":"上交所","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2476184870?lang=zh_cn&edition=full","pubTime":"2024-10-17 09:08","pubTimestamp":1729127280,"startTime":"0","endTime":"0","summary":"上证公告（基金）【2024】802号 为促进万家中证港股通创新药交易型开放式指数证券投资基金（以下简称创新药WJ，基金代码:520700）的市场流动性和平稳运行，根据《上海证券交易所基金自律监管规则适用指引第2号——上市基金做市业务》等相关规定，本所同意广发证券股份有限公司自2024年10月17日起为创新药WJ提供一般做市服务。 特此公告。 上海证券交易所 2024年10月17日 \n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2024-10-17/doc-incsvmwi6196942.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2024-10-17/doc-incsvmwi6196942.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0012","HSTECH","YANG","BK1574","161027","BK0183","BK0276","159992","BK1161","BK1564","01776","BK0188","000776","06978","SG9999001093.SGD","BK0028","BK1147"],"gpt_icon":0},{"id":"2475675345","title":"《成都市促进生物医药产业高质量发展的若干政策措施》公开征求意见","url":"https://stock-news.laohu8.com/highlight/detail?id=2475675345","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2475675345?lang=zh_cn&edition=full","pubTime":"2024-10-16 11:13","pubTimestamp":1729048428,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK1583","BK1161","399441","BK1576","161726","BK1141","03347","06978","159992","BK1574"],"gpt_icon":0},{"id":"2475525289","title":"国泰君安：创新药政策利好有望持续推进 中成药集采或迎加速扩面","url":"https://stock-news.laohu8.com/highlight/detail?id=2475525289","media":"智通财经网","labels":["Policy And Regulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2475525289?lang=zh_cn&edition=full","pubTime":"2024-10-15 16:56","pubTimestamp":1728982601,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，国泰君安发布研报称，全链条支持下，创新药多项利好政策在各地陆续出台，后续政策利好有望持续推进。全国中成药联盟第三批和首批扩围接续采购10月开始报量，Q4或有相关集采文件出台，叠加安徽等省集采，预计集采品类加速扩面。化药集采预期稳定，中成药集采或迎加速扩面第十批化药国采预计于24Q4启动和发布相关细则、25Q1进入实质性招投标阶段。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1194157.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Policy And Regulatory","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK0184","BK1574","BK0188","BK0012","BK0183","600030","159992","601211","BK1564","BK1147","01788","BK0276","06030","BK1161","BK0201","BK0028","06978"],"gpt_icon":1},{"id":"2475332285","title":"近400只医药股收涨！创新药、中药、连锁药店等板块被券商看好","url":"https://stock-news.laohu8.com/highlight/detail?id=2475332285","media":"大河财立方","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2475332285?lang=zh_cn&edition=full","pubTime":"2024-10-14 16:05","pubTimestamp":1728893100,"startTime":"0","endTime":"0","summary":"看好包括创新药、医疗器械、医疗服务及医美、中药等赛道相关公司。同时，中航证券提到，在当下宽货币力度大幅加码、市场经济有望持续向好的经济预期下，板块有望逐步向好，且在普涨震荡后逐步分化，短期内建议重点关注创新药械及其产业链、线下药房或连锁药店、兼具消费和院内需求的医疗服务行业等方向。中邮证券认为，医药流通和ICL板块有望受益于财政政策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2024-10-14/doc-incspfhy8207814.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2024-10-14/doc-incspfhy8207814.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","06978","09939","159938","BK1515","BK1574","159992"],"gpt_icon":0},{"id":"2475808916","title":"关于同意中信证券股份有限公司为万家中证港股通创新药交易型开放式指数证券投资基金提供主做市服务的公告","url":"https://stock-news.laohu8.com/highlight/detail?id=2475808916","media":"上交所","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2475808916?lang=zh_cn&edition=full","pubTime":"2024-10-14 09:08","pubTimestamp":1728868080,"startTime":"0","endTime":"0","summary":"上证公告（基金）【2024】762号 为促进万家中证港股通创新药交易型开放式指数证券投资基金（以下简称创新药WJ，基金代码:520700）的市场流动性和平稳运行，根据《上海证券交易所基金自律监管规则适用指引第2号——上市基金做市业务》等相关规定，本所同意中信证券股份有限公司自2024年10月14日起为创新药WJ提供主做市服务。 特此公告。 上海证券交易所 2024年10月14日 \n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2024-10-14/doc-incsnqmc2252821.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2024-10-14/doc-incsnqmc2252821.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1564","BK0196","BK1516","159992","HSCEI","LU1720050803.USD","LU1794554557.SGD","LU1997245094.SGD","BK0188","LU1064131003.USD","LU1997244956.HKD","06978","BK1574","LU2495084118.USD","LU2289578879.USD","LU0405327148.USD","YANG","06030","BK0183","BK0012","161027","BK1161","LU0405327494.USD","LU1997245177.USD","LU1328615791.USD","600030","BK0028","BK1147","BK0276","HSTECH","LU2148510915.USD","LU1064130708.USD","BK1521"],"gpt_icon":0},{"id":"2474761095","title":"上海今年第五款国产1类创新药获批上市，获批创新药已超去年","url":"https://stock-news.laohu8.com/highlight/detail?id=2474761095","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2474761095?lang=zh_cn&edition=full","pubTime":"2024-10-11 20:43","pubTimestamp":1728650622,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["09939","BK1100","159992","BK0239","01877","BK1161","BK1574","BK1222","06978","09997","159938","BK1583","159883","688180","09996","BK1515"],"gpt_icon":0},{"id":"2474034627","title":"礼来制药：将投资15亿元用于苏州工厂产能升级，扩大2型糖尿病和肥胖创新药物的生产规模","url":"https://stock-news.laohu8.com/highlight/detail?id=2474034627","media":"财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2474034627?lang=zh_cn&edition=full","pubTime":"2024-10-11 13:31","pubTimestamp":1728624690,"startTime":"0","endTime":"0","summary":"10月11日，礼来制药官方公众号发布礼来投资15亿元升级苏州工厂的消息。据推文披露，礼来中国宣布将投资约15亿元人民币用于其苏州工厂的产能升级，扩大2型糖尿病和肥胖创新药物的生产规模， ...","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun","url":"http://stock.10jqka.com.cn/usstock/20241011/c662327397.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/usstock/20241011/c662327397.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["159992"],"gpt_icon":0},{"id":"2474710296","title":"康方生物自主研发创新药获批新适应症","url":"https://stock-news.laohu8.com/highlight/detail?id=2474710296","media":"经济参考网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2474710296?lang=zh_cn&edition=full","pubTime":"2024-10-10 20:11","pubTimestamp":1728562307,"startTime":"0","endTime":"0","summary":"近日，国家药品监督管理局官网显示，康方生物自主研发的一款创新抗癌PD-1/CTLA-4双特异性抗体开坦尼(卡度尼利单抗注射液)正式获批上市，用于与含氟尿嘧啶类和铂类药物化疗联合治疗局部晚期 ...","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20241010/c662307636.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["159992"],"gpt_icon":0},{"id":"2474710218","title":"康方生物胃癌适应症创新药获批上市 公司回应：将积极筹备医保谈判","url":"https://stock-news.laohu8.com/highlight/detail?id=2474710218","media":"证券日报网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2474710218?lang=zh_cn&edition=full","pubTime":"2024-10-10 20:10","pubTimestamp":1728562244,"startTime":"0","endTime":"0","summary":"10月9日，康方生物传来利好消息：由其自主研发创新药开坦尼(卡度尼利单抗注射液)已被国家药品监督管理局获批，联合含氟尿嘧啶类和铂类药物化疗用于局部晚期不可切除或转移性胃或胃食管结合 ...","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun","url":"http://stock.10jqka.com.cn/hks/20241010/c662307195.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20241010/c662307195.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["159992"],"gpt_icon":0},{"id":"2474716303","title":"海欣股份：\n创新药研发主要包括新药发现、临床研究、药品上市等环节","url":"https://stock-news.laohu8.com/highlight/detail?id=2474716303","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2474716303?lang=zh_cn&edition=full","pubTime":"2024-10-10 19:00","pubTimestamp":1728558038,"startTime":"0","endTime":"0","summary":"证券之星消息，海欣股份10月10日在投资者关系平台上答复投资者关心的问题。劳烦董秘具体科普一下，谢谢海欣股份董秘：投资者您好，创新药研发主要包括新药发现、临床研究、药品上市等环节。目前，公司下属两家医药控股公司没有开展创新药研发业务。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024101000032794.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600851","BK1574","BK0086","BK0028","BK0060","BK0239","BK0188","06978","BK1161","159992"],"gpt_icon":0},{"id":"2474446733","title":"金十数据整理：每日港股市场要闻速递（10月10日 周四）","url":"https://stock-news.laohu8.com/highlight/detail?id=2474446733","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2474446733?lang=zh_cn&edition=full","pubTime":"2024-10-10 09:05","pubTimestamp":1728522327,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK4516","399300","600690","159992","601318","03145","LU0348735423.USD","BK4566","06978","09926","BK0012","02318","LU0417516571.SGD","BK0188","161027","LU0348816934.USD","LU0463099449.HKD","BK0067","01519","LU0348805143.USD","5I4.SI","06837","09969","LU0215105999.USD","06690","07226","601211","82318","IE0034235188.USD","L","LU0348827113.USD","02007","YANG","BK0187","LU","LU0348825331.USD","159982","HSTECH","688428","LU0310799852.SGD","00358","LU0043850808.USD","HSCEI","600837","IE00B775SV38.USD","LU2495084118.USD","02611","IE00BHPRN162.USD","BEST"],"gpt_icon":0}],"profile":{"ret":0,"stockEarnings":[{"period":"1week","weight":0.0083},{"period":"1month","weight":0.2073},{"period":"3month","weight":0.1483},{"period":"6month","weight":0.1115},{"period":"1year","weight":-0.125},{"period":"ytd","weight":-0.1176}],"compareEarnings":[{"period":"1week","weight":0.0136},{"period":"1month","weight":0.2003},{"period":"3month","weight":0.0936},{"period":"6month","weight":0.064},{"period":"1year","weight":0.0852},{"period":"ytd","weight":0.0963}],"serverTime":1729418790421,"compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.0","shortVersion":"4.29.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"创新药(159992)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供创新药(159992)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"创新药,159992,创新药股票,创新药股票老虎,创新药股票老虎国际,创新药行情,创新药股票行情,创新药股价,创新药股市,创新药股票价格,创新药股票交易,创新药股票购买,创新药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"创新药(159992)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供创新药(159992)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}